Introduction
Myelodysplastic syndromes (MDS) are characterized by peripheral blood cytopenias affecting one or more hematopoietic lineages and a predisposition to develop acute myeloid leukemia (AML). 1 Symptoms in MDS are caused by insufficient numbers of circulating erythrocytes, leukocytes and/or platelets. Approximately 50% of MDS patients have cytogenetic abnormalities in their malignant clone. 2, 3 Deletion of 5q is the most common cytogenetic abnormality in MDS, with 10-15% of the patients exhibiting this deletion. 3, 4 It may occur as a sole abnormality or in combination with other cytogenetic abnormalities. The 5qÀ syndrome, a subgroup of MDS, is usually characterized by an elderly female who has refractory anemia, high or normal platelet numbers in the peripheral blood, bone marrow with erythroid dysplasia, hypolobulated megakaryocytes, and a low risk to transform to AML. 5, 6 The 5qÀ syndrome is a hematopoietic stem cell disease, typically affecting 490% of the CD34( þ )CD38(À) hematopoietic stem cells in the bone marrow of these patients. 7 The commonly deleted region (CDR) in the 5qÀ syndrome has been narrowed to a 1.5-megabase interval at 5q32 flanked by DNA segment number D5S413 and the GLRA1 gene. 8 This region is distinctly different and more telomeric compared to the CDR in cases of MDS and AML with loss of 5q and often with other karyotypic changes. 9, 10 As the 5q deletion is the sole karyotypic abnormality in the 5qÀ syndrome, it can be assumed that the genes within the region play a part in the pathogenesis of the disease. However, no causative gene has been found although several within the region have been proposed to play a role, for example, Ras-GTPase-activating protein SH3 domainbinding (G3BP), interleukin 17B precursor (IL17B), plateletderived growth factor receptor-b (PDGFRB), colony-stimulating factor-1 receptor precursor (CSF1R) and secreted protein, acidic and rich in cysteine (SPARC).
SPARC is a matricellular protein with complex roles in various biological processes. It helps to regulate the composition of extracellular matrix and binds to many of its resident proteins.
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It can also affect cellular proliferation, differentiation, migration and cell adhesion.
12 SPARC-null mice exhibit early cataract formation, 13 increased deposition of subcutaneous and abdominal fat 14 and accelerated wound healing. 12 Interestingly, bone marrow-derived SPARC can inhibit the binding of thrombospondin to the surface of platelets, and, thereby, inhibit platelet aggregation. 15, 16 Recently, SPARC was shown to inhibit breast cancer cell invasion, platelet aggregation and metastasis. 17 Increased methylation of SPARC in lung and pancreatic tumors is consistent with its role as a potential tumor suppressor gene that is silenced in selected cancers. 18, 19 However, the role of SPARC in hematopoiesis remains unknown.
In this study, we measured the expression of genes within the CDR of the 5qÀ syndrome by real-time reverse-transcription (RT)-PCR. The genes with the most prominent decrease in expression were solute carrier family 36, member 1 (SLC36A1), G3BP, antioxidant protein 1(ATOX1), CSF1R, ribosomal protein S14 (RPS14), PDGFRB, Nef-associated factor 1 (TNIP1), annexin VI (ANAX6) and SPARC. We studied the role of SPARC in hematopoiesis and found a significant decrease in circulating platelets in SPARC-null mice compared to their wild-type counterparts. The capacity of bone marrow cells to form erythroid burst-forming units (BFU-E) was equally impaired; however, no difference was noted between wild-type and SPARC-null mice in the ability to form erythroid colony-forming units (CFU-E), granulocyte/monocyte colony-forming units (CFU-GM) or megakaryocyte colony-forming units (CFU-Mk).
We conclude that SPARC affects hematopoiesis, although it cannot account for the entire clinical phenotype of the 5qÀ syndrome. The 5qÀ syndrome is likely to be a result of the insufficiency of several genes within the deleted region, one of which is SPARC.
Materials and methods

Cell lines and patient cells
The KG-1 cell line has previously been described; 20 the TP-1 cell line was a gift from Dr K Kitamura (Tokyo, Japan). The NB-4 cell line was from Dr Lanotte (Paris, France), HEL cells were from Dr Papayannopoulou (Seattle, WA, USA) and the HL-60 cells were provided by Dr Collins (Seattle, WA, USA). The U937 cell line was purchased from American Type Culture Collection (Manassas, VA, USA).
Mononuclear cells from bone marrow of patients were purified by Ficoll gradient. MDS patients were diagnosed according to the FAB and WHO classifications. Twelve with the 5qÀ syndrome were studied; each had 5q deletion as a sole chromosomal abnormalities and characteristic clinical and morphologic features. All but one patient were women. Of the 14 non-5qÀ MDS patients, 10 were men and 4 were women. The protocol was approved by the Local Ethical Committee (CPPRB) of the Centre Hospitalier Universitaire de Nice.
SPARC-null mice
C57BL/6 Â 129SVJ SPARC-null mice were generated as described. 21 SPARC-null and wild-type mice were housed in a modified, pathogen-free facility. The mice were euthanized at either 6 to 8 weeks or at 12 months of age by anesthetized cervical dislocation (isofluorane inhalation) or by CO 2 overdose, followed by cervical dislocation. The femurs were dissected and kept on ice before they were flushed, and the cells were resuspended in MEM (Invitrogen, Carlsbad, CA, USA), containing 2% fetal calf serum (FCS). Mononuclear cells were separated on Ficoll (Cellgro, Herndon, VA, USA). For peripheral blood counts, blood was aspirated from the heart at the time of euthanization. Samples were analyzed according to standard procedures by Phoenix Central Laboratory (Everett, WA, USA).
Real-time RT-PCR
Total RNA was extracted by the use of QIAprep Spin Miniprep Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer's instructions. For cDNA synthesis, RNA was reversetranscribed using Superscript II RT as described by the manufacturer (Invitrogen). Expression levels were measured by real-time RT-PCR. Levels of b2-microglobulin and b-actin were internal reference standards. Reactions were performed with Platinum Taq DNA polymerase (Invitrogen) and SYBRGreen I (Molecular Probes, Eugene, OR, USA). Reactions were performed in triplicate with an iCycler iQ system (Biorad, Hercules, CA, USA). For each sample, levels of the target gene and reference gene were determined from standard curves.
Colony-forming assay
Mononuclear bone marrow cells from wild-type and SPARCnull mice were resuspended in methylcellulose medium M3234 for CFU-E (2 Â 10 5 cells/ml), and in M3434 for CFU-GM and BFU-E (2 Â 10 4 cells/ml; StemCell Technologies Inc., Vancouver, Canada). EPO (Ortho Biotech, Bridgewater, NJ, USA) was added to the CFU-E and BFU-E colonies at a concentration of 3 U/ml. Cells were plated in six-well plates in a volume of 1 ml and were incubated at 371C in a humidified atmosphere containing 5% CO 2 . CFU-E were counted after 3 days, and CFU-GM and BFU-E were counted after 8 days, with an inverted microscope. Colony type was established by morphology. To ensure accuracy, we plucked representative colonies from the plates, centrifuged them onto slides, stained the cells with Wright-Giemsa stain, and, subsequently, examined them by light microscopy. BFU-E colonies were stained with benzidine. For the CFU-Mk assay, bone marrow cells (1 Â 10 5 ) were cultured with MegaCult-C media (StemCell Technologies) in the presence of 10 ng/ml recombinant murine IL-3 (Calbiochem, San Diego, CA, USA), 20 ng/ml recombinant human IL-6 (Calbiochem) and 50 ng/ml recombinant human TPO (Calbiochem). After culture for 7 days, colonies were stained with acetylcholinesterase (AchE). CFU-Mk colonies were defined as at least three megakaryocytes in a cluster.
Flow cytometry
Evaluation of mononuclear bone marrow cells from wild-type and SPARC-null mice was performed by standard flow cytometry on a FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA) instrument with identical parameters between samples, using appropriate fluorochrome-conjugated monoclonal antibodies against cell surface markers to TER119, CD43, CD4, CD8, CD41, and an appropriate isotype control (Calbiochem, La Jolla, CA, USA). Flow cytometry data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA).
Results
Expression of genes within the CDR
The mRNA levels of the 33 genes within the CDR that are known to be expressed in CD34-positive hematopoietic stem Common deleted genes in the 5qÀ syndrome S Lehmann et al cells 8 were examined in mononuclear cells from 12 patients with the 5qÀ syndrome. The expression levels were compared to those of the mononuclear bone marrow cells from patients with MDS, but having a normal karyotype. Figure 1 shows the genes with the most pronounced downregulation. The solute carrier SLC36A1 had the lowest average expression, with an 89% decrease compared to non-5qÀ MDS samples. Other strongly downregulated genes included G3BP (79% decreased), CSFR1 (76% decreased), ATOX1 (76% decreased), RPS14 (75% decreased), PDGFRB (73% decreased), TNIP (72% decreased) and SPARC (71% decreased). From these, as well as, from examination of expression of the RNAs in different tissues, including variation in hematopoietic cells, as shown in the SymAtlas (http://symatlas.gnf.org), and the known functions of the genes in the context of the pathogenesis of MDS, we selected several genes for further studies.
SPARC is a matricellular protein with diverse functions. 11 It regulates extracellular matrix formation, inhibits cell proliferation, has de-adhesive properties, and is methylated in lung and pancreatic cancer cells, consistent with its role as a tumor suppressor gene. 12, 18, 19 Except for an anti-adhesive effect on platelets, its effects on hematopoiesis are largely unknown. Figure 2a shows the expression of SPARC in each sample from 12 5qÀ patients and 14 MDS patients with normal karyotype, together with its levels in seven leukemic cell lines. The mean expression ratio of SPARC was significantly lower in the 5qÀ samples compared to the non-5qÀ samples (Po0.05). The expression levels in the cell lines were lower than in both of the MDS patient groups. HEL, K562 and TP-1 cells showed higher levels of SPARC mRNA than in the NB-4 and KG-1 cells, whereas levels in U937 and HL-60 cells were only slightly above the level of detection.
G3BP has diverse effects on cellular processes, including its role as a downstream effector of Ras signaling. 22 G3BP was strongly downregulated in the 5qÀ samples compared to the control samples (Po0.005). In contrast to SPARC, the expression of G3BP in the myeloid cell lines was higher compared to both MDS patient groups (Figure 2b ). K562 and HL-60 cells exhibited especially high expression of G3BP.
ATOX1 is an antioxidant protein and a copper chaperone that transports copper intracellularly and detoxifies the cells from excessive amounts of this metal. 23 Even though the mean ATOX1 expression in the 5qÀ samples was just 24% of that of the MDS samples with normal karyotype, the levels were very low compared to the myeloid leukemic cell lines; the cell lines had almost 100-fold increased levels (Figure 2c ). HEL and HL-60 cells showed the highest expression. Finally, RPS14, a ribosomal protein and a component of the S40 ribosomal subunit, had a mean expression level that was 25% of that of the non-5qÀ samples (Po0.05; Figure 2d ). mRNA levels in the myeloid cell lines were slightly higher compared to those in the MDS samples.
Hematopoietic clonogenic growth in SPARC-null mice
To study the importance of SPARC in the hematopoietic system, we performed colony-forming assays on bone marrow cells from wild-type and SPARC-null mice. Figure 3 shows the results (mean7s.d.) of one representative experiment from four wildtype and four SPARC-null mice. In the case of BFU-E, a significant difference occurred, with the bone marrow from the null mice forming fewer colonies (P ¼ 0.03; Figure 3a) . No significant difference in CFU-E formation occurred between SPARC-null and wild-type mice, although a tendency to form fewer colonies was observed in SPARC-null mice (Figure 3b) . No difference was found in the formation of CFU-GM or CFUMk, although the latter tended to be lower in the SPARC-null mice (Figures 3c and d) . These results indicate a role for SPARC in erythroid development.
Blood counts, flow cytometry and bone marrow morphology in SPARC-null mice
Peripheral blood from 1-year-old wild-type and SPARC-null mice was analyzed (Table 1) . Hemoglobin, hematocrit, mean corpuscular volume (MCV) and red blood cell (RBC) count were slightly lower in the null mice, but the differences were not statistically significant. The only statistically significant difference between wild-type and SPARC-null mice was their platelet counts. The mice-lacking SPARC had an average platelet count of 448 K/ml, ranging from 391 to 537 K/ml, whereas wild-type animals had an average of 600 K/ml, ranging from 553 to 627 K/ ml (P ¼ 0.008). The white blood cell (WBC) count tended to be higher in SPARC-null mice.
Bone marrow mononuclear cells from wild-type and SPARCnull mice were analyzed by flow cytometry for hematopoietic subpopulations, including erythroid marker (TER119), stem cell marker (CD34), T-cell markers (CD8 and CD4), as well as, the platelet and megakaryocyte marker (CD41; Table 2 ). None of the markers showed a statistically significant difference, but the difference in the erythroid population (TER119-positive) was Common deleted genes in the 5qÀ syndrome S Lehmann et al close to significant (P ¼ 0.07); nevertheless, the difference was modest, with 11.1% (71.3%) erythroid progenitor cells in wildtype mice and 9.1 % (71.0%) in SPARC-null mice. Cytospin slides were also made from the bone marrow of the mice, and morphology was examined after staining with MayGiemsa reagent. No differences were noted, neither in the percentage of megakaryocytes, erythroid or myeloid cells, nor in their morphologic feature. Eosin-hematoxylin staining was also performed on sections of the femurs; no differences in cellularity or morphology were observed (data not shown).
Discussion
The CDR in the 5qÀ syndrome has been defined as a 1.5-Mb region on human 5q32. 8 It spans approximately 40 genes, of which 33 are expressed in CD34-positive hematopoietic stem cells. This study was initiated by measuring the expression of these 33 genes in samples from patients with the 5qÀ syndrome, in comparison to the expression in samples from patients with MDS with normal karyotype. Genes such as SLC36A1, G3BP, ATOX1, CSF1R, RPS14, PDGFRB, TNIP1, SPARC and ANAX6 showed the most pronounced decrease in expression, all exhibiting more than 50% decrease. Several of these genes may be of interest for the development of MDS, such as, G3BP, a downstream effector of the Ras-signaling pathway;
22 ATOX1, an anti-oxidant copper chaperone; 23 CSFR1 (also known as either fms or M-CSF receptor), a tyrosine kinase receptor; 24 and RPS14, a component of the 40S ribosomal subunit. Interestingly, RPS19, also a component of the S40 subunit, is often mutated in Diamond-Blackfan anemia and when its expression is inhibited in mice, this causes impaired erythropoiesis. 25 SPARC is a secreted matricellular protein with diverse activities.
11 Several identified functions of SPARC could influence neoplastic disease, such as its effects on proliferation, differentiation, cell migration, invasiveness of tumors and adhesion. 12 A recent study showed that SPARC inhibits metastasis, as well as, platelet aggregation and tumor-induced thrombocytopenia in a breast cancer model. 17 Accumulated data in other cancers suggested that SPARC might be a tumor suppressor gene. Exogenous SPARC inhibited proliferation and induced apoptosis of ovarian cancer cells. 26 Other investigators showed that forced expression of SPARC inhibited growth of human ovarian cancer cells in immunodeficient mice and in breast cancer cells in vitro.
27 SPARC-null mice exhibited increased proliferation of mesangial cells, 28 as well as, increased insulin growth factor signaling. 29 The protein also suppressed the growth of pancreatic cancer cells and glioma cells. 30 Further studies showed that the SPARC gene was methylated in both pancreatic 18 and lung cancers. 19 Taken together, SPARC may be a tumor suppressor gene, and blunting of its expression in the 5qÀ syndrome may give the cells a growth advantage.
The expression of SPARC, ATOX1, G3BP and RPS14 was also studied in leukemic cell lines. ATOX1 had the highest expression, followed by G3BP and RPS14. SPARC was the only gene that exhibited lower expression in the leukemic cell line compared to the MDS samples. These results confirm that G3BP is associated with proliferation. However, the 100-fold higher expression of ATOX1 in these AML cell lines is surprising, but little is known about the role of ATOX1 in tumors. ATOX1 might be linked to proliferation. In contrast, the low level of SPARC expression in the leukemic cell lines strengthens the hypothesis that its expression might be associated with control of growth of hematopoietic progenitor cells. The AML cell line data could lead to the speculation that the low levels of SPARC mRNA that we noted in the bone marrow of 5qÀ syndrome represent cells at a different stage of differentiation compared to the bone marrow of the non-5qÀ MDS patients or normal individuals. However, the array-based expression data online (http:// www.ncbi.nlm.nih.gov/geo) showed no major differences in SPARC expression between CD34 þ , CD33 þ , CD3 þ and CD19 þ cell subpopulations from normal marrow, suggesting that, in normal hematopoiesis, SPARC does not greatly vary.
We also studied the hematologic phenotype and function of SPARC in SPARC-null compared to wild-type mice. Interestingly, the number of BFU-E formed by bone marrow cells from the null mice was significantly lower compared to that of wildtype mice. However, the capacity to form CFU-E was not significantly impaired, and the CFU-GM or CFU-Mk numbers were not different between wild-type and SPARC-null mice. CFU-E represent late erythroid progenitors, and BFU-E are the primitive erythroid cells more closely related to hematopoietic stem cells. 31 The difference in CFU-E and BFU-E formation in the SPARC-null mice may reflect a defect that affects very early erythroid differentiation, and deserves further study. Differences in the levels of BFU-E versus CFU-E in other mutated mice have previously been noted. 32 Peripheral blood values from SPARC-null versus wild-type mice showed significantly lower levels of platelets. A possible explanation relates to the known loss of the anti-aggregation effect of SPARC on platelets; [15] [16] [17] this could result in their clumping and rapid clearance from the circulation. However, no increased incidence of thrombosis has been reported in mice-lacking SPARC. Hemoglobin, hematocrit, RBC and MCV exhibited somewhat lower values in the SPARC-null mice. However, none of the differences were statistically significant. Although the null mice had lower levels of platelets, no differences were noted in either bone marrow cellularity or morphology between SPARC-null and wild-type mice, including number and appearance of the megakaryocytes, in either cytospin preparations or stained sections of femurs. This result is not surprising, as morphology is a relatively insensitive assessment of the function of the hematopoietic system, given the comparatively slight impact on colony-forming ability and platelet counts in the SPARC-null mice. Flow cytometry for TER119, a murine erythroid marker, tended to be lower in the bone marrows from SPARC-null mice, with a borderline Pvalue. This finding might also be an indication of the moderate impact that SPARC has on hematopoiesis. Clearly, the hematologic picture in the SPARC-null mice is not that of a full 5qÀ MDS presentation. Still, the hematologic abnormalities in these animals indicate that SPARC could play a role in MDS.
Our results show that a number of genes within the CDR in patients with the 5qÀ syndrome are significantly downregulated. For the first time, we show that SPARC affects hematopoiesis, shown by the lower platelet counts in SPARCnull mice, as well as an impaired ability to form BFU-E. However, SPARC-null mice did not present with clinically overt anemia. This observation supports the concept that the 5qÀ syndrome could be an accumulative lack of normal expression of several genes within the CDR, including SPARC.
